Current ethical issues of clinical trials of drugs for the pathogenetic therapy of multiple sclerosis in the context of the COVID-19 pandemic
The spread of the COVID-19 pandemic posed a serious challenge for scientific and clinical medical institutions in terms of research for new multiple sclerosis (MS) treatments. In this review we discuss the associations between coronavirus infection and MS and provide data on the features of MS patho...
Main Authors: | E. V. Ivashkova, A. M. Petrov, M. V. Votintseva, I. D. Stolyarov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2021-09-01
|
Series: | Неврология, нейропсихиатрия, психосоматика |
Subjects: | |
Online Access: | https://nnp.ima-press.net/nnp/article/view/1652 |
Similar Items
-
Non-biological complex drugs and their analogues in the pathogenetic therapy of multiple sclerosis: Issues of efficacy and safety in clinical use
by: I. D. Stolyarov, et al.
Published: (2015-03-01) -
Current requirements for studies of drugs for the pathogenetic treatment of multiple sclerosis
by: A. N. Boyko, et al.
Published: (2019-12-01) -
Safety of pathogenetic therapy for multiple sclerosis during the COVID-19 pandemic
by: Andrey M. Petrov, et al.
Published: (2022-06-01) -
New possibilities for the therapy of secondary progressive multiple sclerosis
by: A. M. Petrov, et al.
Published: (2019-12-01) -
Monoclonal Antibodies for Multiple Sclerosis Treatment
by: Filipe Palavra
Published: (2015-09-01)